Articles
What Are IDEAs Made Of: Benefits

What Are IDEAs Made Of: Benefits

Mike Rea is back with the WAIMO view on the world. This week he is asking what the word ‘benefit’ really means when it comes to pharma products. What does 'Benefit' mean? One of the most used and abused words in the world of strategic marketing, but, like so much of the vocabulary traded by its neophytes, it doesn't often come with a definition...

Articles
Difficult issues in pharma going global (part II)

Difficult issues in pharma going global (part II)

In the concluding part of this two part article, Faiz Kermani explores regulations to control trials in emerging markets and asks whether pharma is being ethical enough in these regions. In the first part of this article I looked at the growth of clinical development activity in the emerging pharma markets...

Articles
Difficult issues in pharma going global (part I)

Difficult issues in pharma going global (part I)

In the first piece of a two part article, Faiz Kermani looks at the emergence of clinical trial activity in emerging markets and explores some of the ethical issues. Although the economic downturn has had a negative impact, the global pharmaceutical market is still experiencing strong growth...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. FDA nominee Overton dodges questions on Trump influence
  2. Australia starts probe into AI infiltration of Medicare
  3. Lilly forges $3.35bn alliance with China's InnoCare
  4. Telix to buy radiopharma rival ITM for $1.65bn upfront
  5. Advocacy group pokes holes in Trump's MFN pricing claims

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more